Current Report Filing (8-k)
November 05 2019 - 4:11PM
Edgar (US Regulatory)
false0001498068
0001498068
2019-11-05
2019-11-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 5, 2019
American Renal Associates Holdings, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
Delaware
|
001-37751
|
27-2170749
|
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(IRS Employer
Identification Number)
|
|
|
|
|
|
|
|
500 Cummings Center
|
Beverly,
|
Massachusetts
|
|
01915
|
|
(Address of principal executive offices)
|
|
(Zip code)
|
(978) 922-3080
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
|
|
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
|
|
|
|
|
|
☒
|
Emerging growth company
|
|
|
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
☒
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, $0.01 par value
|
ARA
|
New York Stock Exchange
|
|
|
|
|
|
|
|
|
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On November 5, 2019, American Renal Associates Holdings, Inc. issued a press release announcing its financial and operating results for the third quarter ended September 30, 2019. A copy of the press release is furnished with this report as Exhibit 99.1 and is incorporated by reference into this item.
As provided in General Instruction B.2 of Form 8-K, the information in this Item 2.02 and exhibit contained in this report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section, as amended, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
|
|
|
|
|
|
|
|
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
|
|
|
|
|
|
Exhibit
Number
|
|
Description
|
|
|
|
|
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AMERICAN RENAL ASSOCIATES HOLDINGS, INC.
|
|
|
|
|
|
|
|
Dated:
|
November 5, 2019
|
|
|
|
By:
|
|
/s/ Mark Herbers
|
|
|
|
|
|
|
Name:
|
|
Mark Herbers
|
|
|
|
|
|
|
Title:
|
|
Interim Chief Financial Officer
|
American Renal Associates (NYSE:ARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
American Renal Associates (NYSE:ARA)
Historical Stock Chart
From Apr 2023 to Apr 2024
